Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-05212372 · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Subjects will be assigned to receive either PF-05212372 or placebo in each period |
| Cohort 2 | EXPERIMENTAL | Subjects will be assigned to receive either PF-05212372 or placebo in each period |
| Name | Type | Description |
|---|---|---|
| PF-05212372 | DRUG | Inhaled. Dose Level 1: 50 ug |
| Placebo | DRUG | Inhaled |
Inclusion Criteria: Healthy subjects. (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests). Exclusion Criteria: * Evidence or...
PF-05212372 is an investigational small molecule drug developed by Pfizer, Inc. It was studied as an inhaled therapy in a first-in-human Phase 1 trial in healthy volunteers. The compound has not been approved, and its intended disease indication has not been publicly disclosed.
PF-05212372 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the single Phase 1 study of the compound. No partner or collaborator is identified for this asset.
PF-05212372 is in Phase 1 development. It has completed one first-in-human study, and no active trials are ongoing. The drug remains investigational and has not been approved by the FDA or any other regulator for any indication.
PF-05212372 has been studied in one completed Phase 1 trial, NCT01415102. That first-in-human study enrolled 24 healthy volunteers in Belgium and evaluated safety, toleration, and the time course of plasma concentration after single inhaled doses. It was randomized, double-blind, and controlled.
PF-05212372 was given as single inhaled doses in its Phase 1 trial, NCT01415102. The study assessed safety, toleration, and plasma concentration over time in 24 healthy adult volunteers aged 18 years and older in Belgium. It used a randomized, double-blind, controlled design.